Urachal CancerSymptoms, Doctors, Treatments, Advances & More
Learn About Urachal Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Attila Szendroi practices practicing medicine in Budapest, Hungary. Mr. Szendroi is rated as an Elite expert by MediFind in the treatment of Urachal Cancer. He is also highly rated in 1 other condition, according to our data. His clinical expertise encompasses Urachal Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Bladder Reconstruction, and Cystectomy.
Henning Reis practices practicing medicine in Essen, Germany. Mr. Reis is rated as an Elite expert by MediFind in the treatment of Urachal Cancer. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Urachal Cancer, Bladder Cancer, Urothelial Cancer, Cystectomy, and Prostatectomy.
Tibor Szarvas practices practicing medicine in Budapest, Hungary. Mr. Szarvas is rated as an Elite expert by MediFind in the treatment of Urachal Cancer. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Urachal Cancer, Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.
Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...
Summary: This study is a single-center, multi-cohort, phase II clinical trial. Eligible patients with HER2-positive advanced solid tumors were enrolled after providing informed consent. A total of 90 patients were allocated into three cohorts (30 patients each): those with Extramammary Paget's Disease (EMPD), rare solid tumors, or urothelial carcinoma, who had experienced failure of standard treatment or f...